{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:47:30Z","timestamp":1777456050308,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Interregional Hospital Clinical Research Program (PHRC-I) 2019"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,2]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Salvage prostatic bed radiotherapy (PBRT) is a standard in case of biochemical recurrence following radical prostatectomy (RP) for prostate cancer (PC). The management of isolated prostatic bed recurrence following RP and PBRT is debated. Reirradiation within stereotactic body radiotherapy (SBRT) guided by metabolic imaging could be a relevant option in this case. In parallel, metformin, an economically viable and well-tolerated oral antidiabetic agent, has demonstrated its radiosensitising properties. This phase I\/II clinical trial aims to (i) determine the optimal dose for SBRT reirradiation, (ii) conduct safety assessments and (iii) evaluate the efficacy of the metformin and SBRT combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We conducted a prospective, non-randomised, open-label, multicentre, dose escalation, phase I\/II study involving a minimum of 44 patients. Eligible patients must have biochemical recurrence (Prostate Specific Antigen (PSA)&gt;0.2\u2009ng\/mL and confirmed ascending trend in at least two successive assays), occurring at least 2 years after PBRT and prior RP for PC (including low, intermediate and high risk with a single risk factor) and no Common Terminology Criteria for Adverse Events (CTCAE) grade&gt;=2 toxicity following PBRT. The recurrence should be visible on MRI and\/or Positron Emission Tomography (PET) Choline and\/or PET PSMA, without evidence of pelvic lymph node recurrence or metastatic disease. The primary objective of phase I is to determine the optimal SBRT dose (5\u00d76, 6\u00d76, or 5\u00d75\u2009Gy) based on dose-limiting toxicity (DLT). The dose will be chosen using a time-to-event continual reassessment method based on DLT, defined as CTCAE grade \u22653 gastrointestinal or genitourinary toxicity, or any other grade 4 adverse event. The primary outcome of the phase II is to estimate the efficacy of SBRT in combination with metformin in terms of biological relapse-free survival (bRFS) rate at 3 years. Secondary outcomes include 5-year bRFS rate, early\/late genitourinary and gastrointestinal toxicities, quality of life, biochemical response rate, clinical progression-free survival and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been obtained from the Ethics committee \u201cSUD EST III Bron\u201d Ref.CPP 2020-042B (20.05.07.72735) and the National Agency for the Safety of Medicines (ANSM) Ref. ANSM MEDAECNAT-2020-05-00009. The ethics approval obtained covers all the sites that will take part in this study. The study\u2019s findings will be disseminated through publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04536805\">NCT04536805<\/jats:ext-link>\n                      , Registration Date: 2020-08-17\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100031","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:40:41Z","timestamp":1753346441000},"page":"e100031","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["REPAIR_GETUG P16 relapse in previously irradiated prostate bed: a phase I\/II study of stereotactic ablative reirradiation potentiated by a metformine study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04536805","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alexandre","family":"Joly","sequence":"first","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Blanc Lapierre","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Rio","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loig","family":"Vaugier","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-8891","authenticated-orcid":false,"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de l\u2019Ouest Saint Herblain, Saint-Herblain, Pays de la Loire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2026042806001139000_15.7.e100031.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026042806001139000_15.7.e100031.2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0023"},{"key":"2026042806001139000_15.7.e100031.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"2026042806001139000_15.7.e100031.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.047"},{"key":"2026042806001139000_15.7.e100031.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30454-X"},{"key":"2026042806001139000_15.7.e100031.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31553-1"},{"key":"2026042806001139000_15.7.e100031.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30456-3"},{"key":"2026042806001139000_15.7.e100031.8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.787347","article-title":"Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients","volume":"11","author":"Gonzalez-Moya","year":"2021","journal-title":"Front Oncol"},{"key":"2026042806001139000_15.7.e100031.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62548-5"},{"key":"2026042806001139000_15.7.e100031.10","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-015-0481-2","article-title":"The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer","volume":"16","author":"Jaswal","year":"2015","journal-title":"Curr Urol Rep"},{"key":"2026042806001139000_15.7.e100031.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.08.019"},{"key":"2026042806001139000_15.7.e100031.12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brachy.2020.07.001","article-title":"Salvage low-dose-rate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review","volume":"20","author":"Le Roy","year":"2021","journal-title":"Brachytherapy"},{"key":"2026042806001139000_15.7.e100031.13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.02.051","article-title":"Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy","volume":"61","author":"Mouraviev","year":"2012","journal-title":"Eur Urol"},{"key":"2026042806001139000_15.7.e100031.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174339","article-title":"Stereotactic Re-Irradiation for Local Recurrence after Radical Prostatectomy and Radiation Therapy: A Retrospective Multicenter Study","volume":"13","author":"Perennec","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026042806001139000_15.7.e100031.15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2015.06.003","article-title":"Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy","volume":"93","author":"Koritzinsky","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042806001139000_15.7.e100031.16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"66","author":"Rothermundt","year":"2014","journal-title":"Eur Urol"},{"key":"2026042806001139000_15.7.e100031.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01935-x","article-title":"Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial","volume":"16","author":"Kim","year":"2021","journal-title":"Radiat Oncol"},{"key":"2026042806001139000_15.7.e100031.18","first-page":"9509","article-title":"Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database","volume":"25","author":"Taussky","year":"2018","journal-title":"Can J Urol"},{"key":"2026042806001139000_15.7.e100031.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0687-0"},{"key":"2026042806001139000_15.7.e100031.20","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/2.2.203"},{"key":"2026042806001139000_15.7.e100031.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4817","article-title":"Quality of life three years after diagnosis of localised prostate cancer: population based cohort study","volume":"339","author":"Smith","year":"2009","journal-title":"BMJ"},{"key":"2026042806001139000_15.7.e100031.22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/COC.0b013e31821dee4e","article-title":"Androgen deprivation therapy and definitive radiotherapy for prostate cancer","volume":"36","author":"Mendenhall","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"2026042806001139000_15.7.e100031.23","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/261096","article-title":"Novel insights of oligometastases and oligo-recurrence and review of the literature","volume":"2012","author":"Niibe","year":"2012","journal-title":"Pulm Med"},{"key":"2026042806001139000_15.7.e100031.24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur Urol"},{"key":"2026042806001139000_15.7.e100031.25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2012.09.014","article-title":"Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes","volume":"105","author":"Crouzet","year":"2012","journal-title":"Radiother Oncol"},{"key":"2026042806001139000_15.7.e100031.26","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/j.1464-410X.2009.08990.x","article-title":"Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy","volume":"105","author":"Murota-Kawano","year":"2010","journal-title":"BJU Int"},{"key":"2026042806001139000_15.7.e100031.27","doi-asserted-by":"publisher","DOI":"10.1089\/end.2010.0130"},{"key":"2026042806001139000_15.7.e100031.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.04.005"},{"key":"2026042806001139000_15.7.e100031.29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00345-015-1613-5","article-title":"CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed","volume":"34","author":"Detti","year":"2016","journal-title":"World J Urol"},{"key":"2026042806001139000_15.7.e100031.30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canrad.2016.03.005","article-title":"Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report","volume":"20","author":"Janoray","year":"2016","journal-title":"Cancer Radiother"},{"key":"2026042806001139000_15.7.e100031.31","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150197","article-title":"Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer","volume":"88","author":"Zerini","year":"2015","journal-title":"Br J Radiol"},{"key":"2026042806001139000_15.7.e100031.32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2017.11.007","article-title":"Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer","volume":"30","author":"Loi","year":"2018","journal-title":"Clin Oncol"},{"key":"2026042806001139000_15.7.e100031.33","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180494","article-title":"Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)","volume":"92","author":"Jereczek-Fossa","year":"2019","journal-title":"Br J Radiol"},{"key":"2026042806001139000_15.7.e100031.34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ijrobp.2019.02.041","article-title":"Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy","volume":"104","author":"D\u2019Agostino","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042806001139000_15.7.e100031.35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00071","article-title":"Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results","volume":"9","author":"Olivier","year":"2019","journal-title":"Front Oncol"},{"key":"2026042806001139000_15.7.e100031.36","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"2026042806001139000_15.7.e100031.37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.euo.2023.03.005","article-title":"Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study","volume":"6","author":"Archer","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026042806001139000_15.7.e100031.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy\u2014study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"key":"2026042806001139000_15.7.e100031.39","unstructured":"Jonsson Comprehensive Cancer Center . Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy(EXCALIBUR). 2022."},{"key":"2026042806001139000_15.7.e100031.40","unstructured":"University Hospital Inselspital, Berne . A single arm phase II trial of ultrahypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy. 2023."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:00:52Z","timestamp":1777381252000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,24]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-100031"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100031","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}